Sumeet R. Singh

Burlington, ON L7N3H8, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Journal: Advances in therapy
Published: December 16, 2025

Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada.

Cost-effectiveness of insulin icodec for the treatment of type 2 diabetes in Canada.

Journal: Journal of medical economics
Published: August 25, 2025

Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons.

Network connectivity, between-study heterogeneity and timepoint challenges in generalized myasthenia gravis: a feasibility assessment of indirect treatment comparisons.

Journal: Journal of comparative effectiveness research
Published: May 05, 2025

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

Brain volume loss in relapsing multiple sclerosis: indirect treatment comparisons of available disease-modifying therapies.

Journal: BMC neurology
Published: November 14, 2023

Cost-effectiveness of tezepelumab in Canada for severe asthma.

Cost-effectiveness of tezepelumab in Canada for severe asthma.

Journal: Journal of medical economics
Published: July 07, 2023

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.

Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison.

Journal: Journal of medical economics
Published: May 16, 2022

The Transforming Outcomes for Patients Through Medical Home Evaluation and reDesign (TOPMED) Cluster Randomized Controlled Trial: Cost and Utilization Results.

The Transforming Outcomes for Patients Through Medical Home Evaluation and reDesign (TOPMED) Cluster Randomized Controlled Trial: Cost and Utilization Results.

Journal: Medical care
Published: January 14, 2022

Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review.

Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review.

Journal: BMC neurology
Published: May 20, 2021

Identifying Patients with Significant Problems Related to Social Determinants of Health with Natural Language Processing.

Identifying Patients with Significant Problems Related to Social Determinants of Health with Natural Language Processing.

Journal: Studies in health technology and informatics
Published: August 24, 2019

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).

Journal: Journal of medical economics
Published: March 06, 2019

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis.

Journal: CMAJ open
Published: April 13, 2017

Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes.

Perspectives and experiences of health care professionals and patients regarding treatments for type 2 diabetes.

Journal: Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC
Published: February 05, 2014
Showing 1-12 of 13

Last Updated: 09/26/2026